Accuray Incorporated

ARAY | Healthcare | NASDAQ
$1.41
+0.03 (+2.17%)

Key Metrics

Market Cap
$158.84M
P/E Ratio
-70.50
EPS
$-0.02
Beta
N/A
Dividend Yield
N/A
ROE
-2.84%
Current Ratio
1.62

Company Information

Industry
Medical Devices

About Accuray Incorporated

Accuray Incorporated designs develops manufactures and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States Canada Latin America Australia New Zealand Europe the Middle East India Africa Japan China and rest of the Asia Pacific region It offers the CyberKnife System a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain including tumors on or near the spine and in the breast kidney liver lung pancreas and prostate The company also provides the TomoTherapy System including the Radixact System which allows for integrated radiation treatment planning delivery and data management enabling clinicians to deliver ultraprecise treatments to approximately 50 patients per day iDMS data management system a fully integrated treatment planning and data management systems and Accuray precision treatment planning system a treatment planning and data management systems In addition it offers postcontract customer support installation training and other professional services The company primarily markets its products directly to customers including hospitals and standalone treatment facilities through its sales organization as well as to customers through sales agents and group purchasing organizations in the United States and to customers directly and through distributors and sales agents internationally Accuray Incorporated was incorporated in 1990 and is headquartered in Madison Wisconsin

Recent Earnings Surprises

Date Actual EPS Estimated EPS Surprise
2025-08-13 $0.01 $0.03 -65.6%
2025-04-30 $-0.01 $-0.05 +-80.0%
2025-02-05 $0.02 $-0.01 +-300.0%
2024-11-06 $-0.04 $-0.03 24.5%

Financial Ratios (TTM)

Gross Margin
32.05%
Operating Margin
1.71%
Net Margin
-0.35%
ROA
-0.34%
Price to Book
1.85
Price to Sales
0.35